Patent: 8,182,836
Summary for Patent: 8,182,836
| Title: | Abuse-resistant oral dosage forms and method of use thereof |
| Abstract: | An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist. |
| Inventor(s): | Atul M. Mehta |
| Assignee: | Elite Laboratories Inc |
| Application Number: | US12/478,952 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,182,836
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Instituto Grifols, S.a. | VISTASEAL | fibrin sealant (human) | Frozen | 125640 | November 1, 2017 | 8,182,836 | 2029-06-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,182,836
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2521655 | ⤷ Start Trial |
| European Patent Office | 1615623 | ⤷ Start Trial |
| European Patent Office | 3175846 | ⤷ Start Trial |
| Spain | 2625092 | ⤷ Start Trial |
| United States of America | 2004202717 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
